Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 18NETWORK 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Sarcoma 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 85Gemcitabine 74Carboplatin 68Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × alvocidib × Clear all
NCT00005074 2020-04-09

Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

Canadian Cancer Trials Group

Phase 2 Completed
33 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT00005971 2020-04-09

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Canadian Cancer Trials Group

Phase 2 Completed
17 enrolled
Dermatologic

Melanoma

NCT00005974 2020-04-08

Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Canadian Cancer Trials Group

Phase 2 Completed
18 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡